Cleveland Clinic researchers have successfully developed a therapeutic peptide that blocks aggressive cancer cells from multiplying rapidly. The results highlight a new strategy for developing targeted treatments for triple-negative breast cancer, which currently has no approved options.
Targeted drugs attack cancer cell functions directly, offering a more precise approach to complement broader treatments like chemotherapy. A research team led by Ofer Reizes, PhD, and Justin Lathia, PhD, designed a peptide therapeutic that disrupts the molecular processes behind aggressive cancer growth when delivered into cells.
The drug stopped cancer growth and induced tumor cell death, and only affected cancerous cells in preclinical work. The study was highlighted in the January issue of Molecular Cancer Therapeutics.
